STAA — STAAR Surgical Company stock price, charts and financials

QT66STAAR Surgical Company

STAAR Surgical Company (NASDAQ: STAA) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
24.34
-0.02-0.08%
STAAQT66STAAR Surgical Company·NASDAQ
24.34-0.08%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)-0.42Insider Own35.10%Shs Outstand49.79MPerf Week4.19%
Market Cap1.21BForward P/E25.43EPS next Y0.96Insider Trans3.84%Shs Float49.39MPerf Month-13.46%
Enterprise Value1.12BPEG-EPS next Q-Inst Own-Short Float10.31%Perf Quarter-7.59%
Income-20.98MP/S4.18EPS this Y270.01%Inst Trans-Short Ratio6.26Perf Half Y28.62%
Sales290.38MP/B3.45EPS next Y34.13%ROA-4.66%Short Interest5.09MPerf YTD5.50%
Book/sh-P/C-EPS next 5Y27.38%ROE-6.07%52W High35.84 -32.09%Perf Year34.59%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-1.26%52W Low15.58 56.25%Perf 3Y-56.52%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-5.59% 7.95%Gross Margin76.43%Volatility5.51% 5.45%Perf 5Y-81.53%
Dividend TTM-EV/Sales3.85EPS Y/Y TTM-2.44%Oper. Margin-1.72%ATR (14)1.42Perf 10Y276.51%
Dividend Ex-Date-Quick Ratio4.31Sales Y/Y TTM-7.32%Profit Margin-7.24%RSI (14)41.03Recom2.80
Dividend Gr. 3/5Y-Current Ratio5.12EPS Q/Q173.08%SMA20-5.47%Beta1.25Target Price32.60
Payout0.00%Debt/Eq0.11Sales Q/Q118.60%SMA50-13.38%Rel Volume1.51Prev Close24.36
Employees1,157LT Debt/Eq0.09EarningsAug 12SMA2000.10%Avg Volume895.43KPrice24.34
IPO DateFeb 24, 1992Option/ShortYes / YesEPS/Sales Surpr.600.84% 18.81%Net Debt/EBITDA23.03Volume1,353,648Change-0.08%
Analyst Ratings
DateActionAnalystRatingTarget
May-14-26ReiteratedStifel Nicolaus$18$31
May-14-26UpgradeWedbushNeutralOutperform$26$40
May-14-26ReiteratedCanaccord GenuityBuy$27$32
May-14-26ReiteratedMizuhoNeutral$27
May-14-26ReiteratedPiper SandlerNeutral$33
Apr-09-26UpgradeCanaccord GenuityHoldBuy$22$27
Mar-04-26ReiteratedStifel Nicolaus$19$18
Feb-09-26ReiteratedStifel Nicolaus$28$19
Feb-03-26InitiatedWedbushNeutral$26
Jan-16-26ResumedMorgan StanleyUnderweight$13
Latest News
Company

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
1/2/2026
FY 2024
12/27/2024
FY 2023
12/29/2023
FY 2022
12/30/2022
FY 2021
12/31/2021
FY 2020
1/1/2021
FY 2019
1/3/2020
FY 2018
12/28/2018
Total Revenue291239314322284230163150124
Cost of Goods Sold Incl. D&A695774706152453832
Gross Profit22318224025322317911811292
Selling, General and Administrative Excl. Other176188198180144111807563
Research and Development384054443634322522
Other Operating Expense1300100000
Operating Income-6-46-132844337127
Interest Expense
000000000
Unusual Expense
Non-Operating Income (Expense)-15-36462-2110
Net Income Before Taxes-20-82-93446318137
Income Taxes2-21112642-12
Consolidated Net Income-21-80-202140286145
Net Income From Continuing Operations-21-80-202140286145
Net Income-21-80-202140286145
EPS (Recurring)-0.42-1.62-0.410.440.830.520.130.320.11
EPS (Basic, Before Extraordinaries)-0.42-1.62-0.410.440.830.520.130.320.11
EPS (Diluted)-0.42-1.62-0.410.430.800.500.120.300.11
EBITDA-5-74-239503510169
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio72.5860.68182.60660.17114.60284.18
Price To Sales Ratio4.184.943.784.758.2018.6622.3610.0811.34
Gross Margin76.6376.1576.4378.5778.5277.8372.3974.6774.19
Operating Margin-2.06-19.25-4.148.7015.4914.354.298.005.65
Net Margin-7.22-33.47-6.376.5214.0812.173.689.334.03
Shares Outstanding505049494847464445
Market Capitalization1,2171,1801,1861,5292,3304,2913,6441,5131,407
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$35.93$30.32$24.72$19.12$13.51 Close Price0.00M10.27M20.53M30.80M41.06MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Butcher Arthur CDirectorJun 18 '26Option Exercise0.005,34109,549Jun 22
SILVERMAN LOUDirectorJun 18 '26Option Exercise0.0010,683011,158Jun 22
Jiang WeiDirectorJun 18 '26Option Exercise0.0010,683077,127Jun 22
Foust WarrenInterim Co-CEO and Pres. & COOMay 15 '26Option Exercise0.0032,990032,990May 19
Michna MagdaChief Development OfficerMay 15 '26Option Exercise0.0019,795019,795May 19
ANDREWS DEBORAH JInterim Co-CEO and CFOMay 15 '26Option Exercise0.0015,699015,699May 19
Michna MagdaChief Development OfficerMar 14 '26Option Exercise0.0017,595036,001Mar 16
Foust WarrenInterim Co-CEO and Pres. & COOMar 14 '26Option Exercise0.0029,325063,588Mar 16
Foust WarrenInterim Co-CEO and Pres. & COOMar 12 '26Option Exercise0.008,175034,263Mar 16
Michna MagdaChief Development OfficerMar 12 '26Option Exercise0.006,178020,622Mar 16
BROADWOOD PARTNERS, L.P.director, 10 percent owner:Mar 13 '26Buy18.61316,0175,882,65616,123,842Mar 13
BROADWOOD PARTNERS, L.P.director, 10 percent owner:Mar 12 '26Buy18.12299,4325,424,33015,807,825Mar 13
BROADWOOD PARTNERS, L.P.director, 10 percent owner:Mar 11 '26Buy17.5254,764959,55815,508,393Mar 13
Jiang WeiDirectorJan 12 '26Option Exercise0.0020,967066,444Jan 14
BROADWOOD PARTNERS, L.P.10% OwnerJan 09 '26Buy22.0527,485606,13815,453,629Jan 13
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.